Organigram Global Inc. OGI
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Organigram Global Inc. (OGI) is a healthcare company listed in the US with a market value of about $117M. In the twelve months to June 30, 2026 it had revenue of $217M and net income of $61M, a net margin of 28.0%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is track record (1/5).
Key numbers: a P/E of 1.9, 5-year revenue growth of 65% a year, a 5-year average ROIC of -14%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 203% above the current price.
About Organigram Global
Organigram Global is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $10M in 2018 to $182M in 2025, growth of about 52.3% a year. It was profitable in 1 of the last 7 years in our data. Its share count fell by 9% over three years (buybacks).
Score: 2.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
Checks not passed
- P/FCF below 20
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- Positive free cash flow
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $217M | $182M | $118M | $111M | $63M | $66M | $61M | $10M |
| Net income | $61M | -$17M | -$34M | -$11M | -$104M | -$104M | -$7M | $16M |
| Free cash flow | -$21M | -$17M | -$635543 | -$65M | -$32M | -$94M | -$108M | -$53M |
| EPS (diluted) | $0.44 | $-0.14 | $-0.24 | $-0.08 | $-0.74 | $-0.74 | $-0.05 | $0.11 |
| Net margin | 28.0% | -9.6% | -28.4% | -9.8% | -165.1% | -156.9% | -11.9% | 165.0% |
| ROIC | — | — | -11.7% | -8.4% | -19.1% | -32.6% | 1.1% | 15.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Organigram Global’s P/E ratio?
About 1.9, based on the last twelve months of diluted earnings per share (forward P/E about 34.5).
Is Organigram Global stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 203% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Organigram Global pay a dividend?
Not currently.
Is Organigram Global a good stock to buy?
We do not give buy or sell advice. Organigram Global scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.